The Patient Access Network (PAN) Foundation commended CMS' decision to ban the use of co-pay accumulator programs when no generic alternatives are available, calling it a significant win for patients who rely on specialty medications with high out-of-pocket costs. The rule allows drug manufacturer coupons for brand name medications to count toward the patient's deductible and annual out-of-pocket cost limit when no generic is available.
According to PAN, while not a total prohibition of these programs, it is an important move to ensure economically vulnerbale patients have access to life-saving specialty medications, many of which do not have generic alternatives.
“Co-pay accumulator programs lead to greater out-of-pocket costs for individuals with life-threatening, chronic and rare diseases,” said Dan Klein, PAN’s president and chief executive officer.. “In situations where there are no generic alternatives, many patients need manufacturer coupons to help pay for their deductibles, co-pays and coinsurance. Otherwise, these patients would be unable to obtain their critical medications without having to make devastating financial trade-offs.”
Dr Kathryn Lindley on Pregnancy-Related Cardiovascular Care Gaps and Training Initiatives
December 8th 2023Cardiologists need skills in risk assessment, contraception counseling, and hypertension management for pregnant patients, according to Kathryn Lindley, MD, FACC, Vanderbilt University Medical Center.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen